The FTC's Ongoing Opposition To Reverse Payments

Law360, New York (May 8, 2008, 12:00 AM EDT) -- The “Drug Price Competition and Patent Term Restoration Act of 1984,” more often called “Hatch-Waxman,” regulates the generic drug industry in the United States. Hatch-Waxman reflects an attempt by Congress to balance incentives for innovation in the pharmaceutical industry with greater public access to the drugs produced by that industry.

These incentives include restoring a period of patent protection to the innovator drug companies lost while waiting for regulatory approval of a drug. At the same time, Hatch-Waxman is intended to provide lower medical costs by...
To view the full article, register now.